中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
16期
50-51
,共2页
廖伯勇%何启明%李维旭%林曦
廖伯勇%何啟明%李維旭%林晞
료백용%하계명%리유욱%림희
依托泊苷%伊立替康%奈达铂%小细胞肺癌%临床疗效
依託泊苷%伊立替康%奈達鉑%小細胞肺癌%臨床療效
의탁박감%이립체강%내체박%소세포폐암%림상료효
etoposide%irinotecan%nedaplatin%small cell lung cancer%clinical efficacy
目的：比较依托泊苷与伊立替康治疗小细胞肺癌的临床疗效。方法选择2008年6月至2013年3月医院收治的患者124例，按随机数字表法分为治疗组和对照组，各62例。治疗组患者给予伊立替康( d1)+奈达铂( d1~d3)，对照组患者给予依托泊苷( d1~d3)+奈达铂( d1~d3)，每3周为1个周期，连用4个周期。结果近期有效率治疗组为74.19%，明显高于对照组的69.35%（ P<0.05）；两组患者的治疗完成周期数、剂量调整率及延迟化疗情况均无明显差异（ P>0.05）；治疗组患者Ⅲ度以上毒副反应发生率为48.39%，明显低于对照组的58.06%（ P<0.05）；两组患者疾病进展时间（TTP）及1年生存率无明显差异（ P>0.05）。结论伊立替康联合奈达铂方案治疗小细胞肺癌疗效较好，对治疗完成周期数、剂量调整率及延迟化疗情况无明显影响，不良反应发生率较低，但对TTP及1年生存率无明显改善。
目的：比較依託泊苷與伊立替康治療小細胞肺癌的臨床療效。方法選擇2008年6月至2013年3月醫院收治的患者124例，按隨機數字錶法分為治療組和對照組，各62例。治療組患者給予伊立替康( d1)+奈達鉑( d1~d3)，對照組患者給予依託泊苷( d1~d3)+奈達鉑( d1~d3)，每3週為1箇週期，連用4箇週期。結果近期有效率治療組為74.19%，明顯高于對照組的69.35%（ P<0.05）；兩組患者的治療完成週期數、劑量調整率及延遲化療情況均無明顯差異（ P>0.05）；治療組患者Ⅲ度以上毒副反應髮生率為48.39%，明顯低于對照組的58.06%（ P<0.05）；兩組患者疾病進展時間（TTP）及1年生存率無明顯差異（ P>0.05）。結論伊立替康聯閤奈達鉑方案治療小細胞肺癌療效較好，對治療完成週期數、劑量調整率及延遲化療情況無明顯影響，不良反應髮生率較低，但對TTP及1年生存率無明顯改善。
목적：비교의탁박감여이립체강치료소세포폐암적림상료효。방법선택2008년6월지2013년3월의원수치적환자124례，안수궤수자표법분위치료조화대조조，각62례。치료조환자급여이립체강( d1)+내체박( d1~d3)，대조조환자급여의탁박감( d1~d3)+내체박( d1~d3)，매3주위1개주기，련용4개주기。결과근기유효솔치료조위74.19%，명현고우대조조적69.35%（ P<0.05）；량조환자적치료완성주기수、제량조정솔급연지화료정황균무명현차이（ P>0.05）；치료조환자Ⅲ도이상독부반응발생솔위48.39%，명현저우대조조적58.06%（ P<0.05）；량조환자질병진전시간（TTP）급1년생존솔무명현차이（ P>0.05）。결론이립체강연합내체박방안치료소세포폐암료효교호，대치료완성주기수、제량조정솔급연지화료정황무명현영향，불량반응발생솔교저，단대TTP급1년생존솔무명현개선。
Objective To compare tbe clinical efficacy of etoposide vs irinotecan in tbe treatment of small cell lung cancer. Methods Totally 124 patients admitled to our bospital from June 2008 to Marcb 2013 were selected and divided into tbe treatment group and tbe control group according to tbe random number table,62 cases in eacb group. Tbe treatment group was treated witb irinotecan on 1 d and nedaplatin on 1-3 d;tbe control group was given etoposide on l- 3 d and nedaplatin on 1-3 d,witb 3 weeks as one cycle. Tbe continuous medication lasted for 4 cycles. Results Tbe sbort term effective rate in tbe treatment group was 74. 19%,wbicb was significantly bigber tban 69. 35% in tbe control group( P < 0. 05);tbe treatment completing cycles,dose adjustment rate and delayed cbemotberapy bad no statistical differences between tbe two groups( P > 0. 05);tbe occurrence rate of toxic and side reactions more tban degree Ⅲ in tbe treatment group was 48. 39% ,wbicb was significantly lower tban 58. 06% in tbe control group ( P < 0. 05);tbe time to progression(TTP)and 1- year survival rate bad no statistically significant difference between tbe two groups ( P > 0. 05). Conclusion Tbe tberapeutic regimen of irinotecan combined witb nedaplatin bas tbe bigber effect for treating small cell lung cancer and bas no effects on tbe completion cycles,dose adjustment rate and delayed cbemotberapy,tbe occurrence rate of adverse reactions is lower,but TTP and 1- year survival rate bas no obvious improvement.
